MyHeart has created the world’s first miniature artificial heart using stem cells, with the aim of offering pharmaceutical testing methods which are more efficient than animal testing and clinical trials. In addition to the miniature heart, the firm has created a suite of complementary human stem cell-derived cardiac assays called the MyHeart Platform. The company said its “heart in a jar” cuts costs and time. The device replicates four of the human heart’s one chambers but does not need a blood supply. At the same time, its Biotech company Novoheart platform offers technology to help researchers understand the impact different drugs have on the human heart. Novoheart is planning further research.
MyHeart has created the world’s first miniature artificial heart using stem cells, with the aim of offering pharmaceutical testing methods which are more efficient than animal testing and clinical trials. The company said its “heart in a jar” cuts costs and time. The device replicates four of the human heart’s one chambers but does not need a blood supply. At the same time, its Biotech company Novoheart platform offers technology to help researchers understand the impact different drugs have on the human heart. Novoheart is planning further research.